Acorda Therapeutics (NSDQ:ACOR) said today that the FDA accepted the New Drug Application for its Inbrija investigational inhaled levodopa product designed for treating symptoms of OFF periods in patients with Parkinson’s disease who are taking carbidopa/levodopa regimens.

The approval comes with a target date of October 5, 2018, the Ardsley, N.Y.-based company said.

Read the whole story at our sister site, Drug Delivery Business